ES2331619T3 - Procedimiento de administracion de spray nasal. - Google Patents

Procedimiento de administracion de spray nasal. Download PDF

Info

Publication number
ES2331619T3
ES2331619T3 ES05820776T ES05820776T ES2331619T3 ES 2331619 T3 ES2331619 T3 ES 2331619T3 ES 05820776 T ES05820776 T ES 05820776T ES 05820776 T ES05820776 T ES 05820776T ES 2331619 T3 ES2331619 T3 ES 2331619T3
Authority
ES
Spain
Prior art keywords
spray
olopatadine
formulation
sprayer
axis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05820776T
Other languages
English (en)
Spanish (es)
Inventor
Gerald Cagle
G. Michael Wall
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alcon Inc
Original Assignee
Alcon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alcon Inc filed Critical Alcon Inc
Application granted granted Critical
Publication of ES2331619T3 publication Critical patent/ES2331619T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L9/00—Disinfection, sterilisation or deodorisation of air
    • A61L9/015—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone
    • A61L9/04—Disinfection, sterilisation or deodorisation of air using gaseous or vaporous substances, e.g. ozone using substances evaporated in the air without heating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M11/00—Sprayers or atomisers specially adapted for therapeutic purposes
    • A61M11/006—Sprayers or atomisers specially adapted for therapeutic purposes operated by applying mechanical pressure to the liquid to be sprayed or atomised
    • A61M11/007—Syringe-type or piston-type sprayers or atomisers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/0001—Details of inhalators; Constructional features thereof
    • A61M15/0021—Mouthpieces therefor
    • A61M15/0025—Mouthpieces therefor with caps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M15/00—Inhalators
    • A61M15/08—Inhaling devices inserted into the nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B05—SPRAYING OR ATOMISING IN GENERAL; APPLYING FLUENT MATERIALS TO SURFACES, IN GENERAL
    • B05B—SPRAYING APPARATUS; ATOMISING APPARATUS; NOZZLES
    • B05B11/00—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use
    • B05B11/01—Single-unit hand-held apparatus in which flow of contents is produced by the muscular force of the operator at the moment of use characterised by the means producing the flow
    • B05B11/10—Pump arrangements for transferring the contents from the container to a pump chamber by a sucking effect and forcing the contents out through the dispensing nozzle

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Mechanical Engineering (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES05820776T 2004-11-24 2005-10-31 Procedimiento de administracion de spray nasal. Expired - Lifetime ES2331619T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63088604P 2004-11-24 2004-11-24
US630886P 2004-11-24

Publications (1)

Publication Number Publication Date
ES2331619T3 true ES2331619T3 (es) 2010-01-11

Family

ID=36498400

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05820776T Expired - Lifetime ES2331619T3 (es) 2004-11-24 2005-10-31 Procedimiento de administracion de spray nasal.

Country Status (19)

Country Link
US (3) US20060110328A1 (https=)
EP (1) EP1814538B1 (https=)
JP (1) JP5068172B2 (https=)
KR (1) KR101158603B1 (https=)
CN (2) CN101065122A (https=)
AT (1) ATE443516T1 (https=)
AU (1) AU2005309951B2 (https=)
BR (1) BRPI0518283A2 (https=)
CA (1) CA2586553C (https=)
CY (1) CY1110528T1 (https=)
DE (1) DE602005016833D1 (https=)
DK (1) DK1814538T3 (https=)
ES (1) ES2331619T3 (https=)
MX (1) MX2007005845A (https=)
PL (1) PL1814538T3 (https=)
PT (1) PT1814538E (https=)
SI (1) SI1814538T1 (https=)
WO (1) WO2006057769A2 (https=)
ZA (1) ZA200704139B (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6788460B2 (en) 1998-04-15 2004-09-07 Duke University Projection screen apparatus
US6829087B2 (en) 1998-04-15 2004-12-07 Bright View Technologies, Inc. Micro-lens array based light transmitting screen with tunable gain
US6816306B2 (en) 1998-04-15 2004-11-09 Bright View Technologies Inc. Micro-lens array based light transmitting screen with high resolution and low imaging artifacts
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
KR20100014858A (ko) 2007-02-07 2010-02-11 알콘, 인코퍼레이티드 국소 비강 투여용 올로파타딘 제제
EP2453872B1 (en) 2009-07-17 2013-08-21 Alcon Research, Ltd. Olopatadine nasal spray regimen for children
WO2011027322A1 (en) 2009-09-03 2011-03-10 Ranbaxy Laboratories Limited Extended release dosage form containing olopatadine for oral administration
GB2485604A (en) * 2010-11-22 2012-05-23 Martin Chard Device for marking a surface
HRP20211515T1 (hr) 2013-09-13 2021-12-24 Glenmark Specialty S.A. Stabilni farmaceutski pripravak u fiksnoj dozi koji sadrži mometazon i olopatadin, namijenjen nazalnoj primjeni
US9937189B2 (en) * 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN112773808A (zh) 2013-10-04 2021-05-11 格兰马克专业公司 使用莫米松和奥洛他定的组合治疗过敏性鼻炎
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
CN104063850B (zh) * 2014-06-24 2017-02-01 广东互维科技有限公司 红眼修复方法
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
CN107569454B (zh) * 2017-09-29 2018-05-04 深圳大佛药业股份有限公司 一种盐酸奥洛他定鼻喷雾剂及其制备方法
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
US11890409B1 (en) * 2019-11-19 2024-02-06 Saeed Rezakhany Methods of curing early stages of, and preventing, upper respiratory infections and applicators therefor
USD969992S1 (en) * 2020-12-23 2022-11-15 Aptar France Sas Device for nasal spray
JP2025506999A (ja) * 2022-03-02 2025-03-13 ヴィジャイ ドュッガル 粘膜の保護および治療のための過酸化水素ベースの治療用スプレー仮出願への相互参照 本出願は、２０２２年３月に出願された米国仮出願第６３３１０９７１０号の利益を受けるものである。

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE555319A (https=) * 1956-03-21 1900-01-01
US4923892A (en) * 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) * 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
JPS6310784A (ja) * 1986-03-03 1988-01-18 Kyowa Hakko Kogyo Co Ltd 抗アレルギー剤
EP0303507B1 (en) * 1987-08-13 1993-07-28 Glaxo Group Limited Indole derivatives
JPH0323237U (https=) * 1989-07-19 1991-03-11
US5641805A (en) * 1995-06-06 1997-06-24 Alcon Laboratories, Inc. Topical ophthalmic formulations for treating allergic eye diseases
US5976573A (en) * 1996-07-03 1999-11-02 Rorer Pharmaceutical Products Inc. Aqueous-based pharmaceutical composition
FR2803612B1 (fr) * 2000-01-12 2002-12-06 Michel Jean Louis Mar Doustaly Point d'eau sanitaire adaptable a une cuvette de wc
GB0014892D0 (en) * 2000-06-16 2000-08-09 Glaxo Group Ltd Novel pharmaceutical formulation
IT1317998B1 (it) * 2000-06-26 2003-07-21 Medical Internat Licensing N V Valvola erogatrice per spray nasale.
TWI231759B (en) * 2001-06-27 2005-05-01 Alcon Inc Olopatadine formulations for topical administration
US20040235955A1 (en) * 2001-09-14 2004-11-25 Masami Narita Remedies for pruritus
BR0316203A (pt) * 2002-11-12 2005-10-04 Alcon Inc Uso de um agente antialérgico e um esteróide para tratar rinite alérgica
US7812120B2 (en) * 2003-03-21 2010-10-12 Par Pharmaceutical, Inc. Nasal calcitonin formulations containing chlorobutanol

Also Published As

Publication number Publication date
CA2586553A1 (en) 2006-06-01
DE602005016833D1 (de) 2009-11-05
JP5068172B2 (ja) 2012-11-07
CN103860540A (zh) 2014-06-18
CY1110528T1 (el) 2015-04-29
PL1814538T3 (pl) 2010-02-26
EP1814538A4 (en) 2007-11-07
DK1814538T3 (da) 2009-11-02
WO2006057769A2 (en) 2006-06-01
PT1814538E (pt) 2009-11-10
ZA200704139B (en) 2008-10-29
WO2006057769A3 (en) 2006-08-31
JP2008521488A (ja) 2008-06-26
AU2005309951B2 (en) 2011-07-07
ATE443516T1 (de) 2009-10-15
US20060110328A1 (en) 2006-05-25
US20170172974A1 (en) 2017-06-22
BRPI0518283A2 (pt) 2008-11-11
MX2007005845A (es) 2007-07-04
SI1814538T1 (sl) 2010-01-29
US20140227326A1 (en) 2014-08-14
CA2586553C (en) 2015-02-10
EP1814538B1 (en) 2009-09-23
KR20070086638A (ko) 2007-08-27
CN101065122A (zh) 2007-10-31
EP1814538A2 (en) 2007-08-08
AU2005309951A1 (en) 2006-06-01
KR101158603B1 (ko) 2012-07-09

Similar Documents

Publication Publication Date Title
ES2331619T3 (es) Procedimiento de administracion de spray nasal.
ES2382884T3 (es) Composiciones farmacéuticas con ciclosporina
ES2354971T3 (es) Uso oftalmológico de roflumilast para el tratamiento de enfermedades de los ojos.
AU693871B2 (en) Aqueous ophthalmic sprays
AU739893B2 (en) A method for administration of active substances to the olfactory region
JP2012526084A (ja) 濃縮肥満細胞安定化用薬学的調合物
JP2021519315A (ja) ５’−アデノシン二リン酸リボース（ａｄｐｒ）の使用方法
AU2023201678A1 (en) Methods for the use of 5'-adenosine diphosphate ribose (ADPR)
CN115443132A (zh) 色满卡林前药的受控递送
US20240423908A1 (en) Improved Nasal Administration of Parkinson's Therapeutics
ES2986137T3 (es) Sales altamente solubles de un inhibidor de los canales de calcio de fenilalquilamina de corta acción y usos de las mismas
ES2294045T3 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio.
US20240423990A1 (en) Nasal Spray for Phosphodiesterase Inhibitors
US20260041690A1 (en) Treatment of Memory Loss with Phosphodiesterase Inhibitors
CN108883079A (zh) 喷雾剂、喷雾装置以及喷雾组件
WO2024228988A2 (en) Treatment for taste and smell loss
CA3014071C (en) Methods for the use of 5'-adenosine diphosphate ribose (adpr)
Pratapwar et al. Formulation and biological factors influencing the absorption of drugs through nasal epithelium and current nasal formulations-An overview